Tirzepatide and Gallbladder Side Effects: What the Research Shows

*Compounded tirzepatide is not FDA-approved. This article is for educational and informational purposes only and does not constitute medical advice. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or changing any medication.*

---

If you are researching tirzepatide and noticed gallbladder problems listed among the potential side effects, you are right to look into it. Gallbladder disease appears in the safety profile of GLP-1 receptor agonists as a class, and tirzepatide carries similar considerations - though the available data suggest the risk pattern may differ from that seen with semaglutide.

This article covers how tirzepatide affects the gallbladder, what the clinical trial data actually show, who faces higher risk, which symptoms warrant urgent attention, and how the tirzepatide risk compares to other GLP-1 medications.

---

How Tirzepatide Affects the Gallbladder

To understand the risk, it helps to understand how the gallbladder normally works. The gallbladder stores bile, a fluid produced by the liver that breaks down dietary fat. When you eat, the gallbladder contracts to push bile into the small intestine. Gallstones develop when bile becomes oversaturated with cholesterol and begins to crystallize - a process accelerated by two factors that are both relevant to GLP-1 therapy.

Rapid weight loss changes bile composition. Any significant caloric deficit, whether from diet, surgery, or medication, causes the liver to excrete more cholesterol into bile. This shifts bile toward a more lithogenic (stone-forming) state. This is a well-established mechanism for gallstone formation during periods of rapid weight loss and is not unique to any particular medication.

GLP-1 receptors are expressed in the gallbladder wall. Activation of these receptors appears to reduce the frequency and strength of gallbladder contractions. Bile that sits in the gallbladder longer rather than cycling through regular emptying is more likely to become concentrated and eventually crystallize. Tirzepatide, as a dual GIP/GLP-1 receptor agonist, activates GLP-1 receptors similarly to other agents in this class.

These two pathways can reinforce each other during the period of most rapid weight loss, which typically occurs in the first several months of treatment.

---

What the Clinical Trials Show

The SURMOUNT-1 trial is the primary source of safety data for tirzepatide in adults with obesity. Published in 2022 in the *New England Journal of Medicine*, this 72-week randomized controlled trial enrolled 2,539 adults with obesity (without type 2 diabetes) and compared tirzepatide 5 mg, 10 mg, and 15 mg weekly to placebo. [1]

Gallbladder-related adverse events - including cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) - were included in the prespecified safety monitoring for SURMOUNT-1. Gallstone events occurred in the tirzepatide groups at rates modestly higher than placebo, consistent with the class effect seen across GLP-1 receptor agonists. The events were largely identified incidentally or through symptom evaluation rather than as acute presentations.

Across the broader SURMOUNT clinical program, which includes trials in adults with obesity both with and without type 2 diabetes, gallbladder events appeared in the safety data at rates consistent with the class effect observed with other GLP-1 receptor agonists. The FDA's prescribing information for both Mounjaro and Zepbound notes cholelithiasis and acute cholecystitis as adverse reactions requiring provider awareness. [2]

How does tirzepatide compare to semaglutide? A 2025 systematic review and meta-analysis published in the *Annals of Saudi Medicine* analyzed 13 randomized controlled trials covering nearly 27,000 adults with obesity. [3] The analysis found that semaglutide was associated with a 2.6-fold increase in the risk of cholelithiasis compared to placebo. Tirzepatide, in the same analysis, did not show a statistically significant increase in biliary risk. This finding is exploratory and should not be interpreted as meaning tirzepatide carries no gallbladder risk, but it does suggest the risk profile may differ between the two agents - an area of ongoing investigation.

The mechanism behind any potential difference remains under study. One hypothesis is that tirzepatide's GIP receptor agonism may partially offset GLP-1-mediated gallbladder relaxation, though this has not been definitively established.

---

Who Faces Higher Risk?

Not all people on tirzepatide face the same gallbladder risk. Several factors increase susceptibility.

Rapid early weight loss. The faster bile composition shifts, the faster stone formation can occur. People who lose significant weight in the first two to three months are at higher risk during that window.

Pre-existing gallbladder conditions. If you have a personal or family history of gallstones, you already carry a higher baseline risk. Adding the weight-loss-related biliary changes on top of an existing predisposition raises that risk further.

Being female. Women develop gallstones at roughly twice the rate of men, a pattern driven in part by estrogen's effects on bile composition and cholesterol metabolism. This baseline difference persists during GLP-1 therapy.

Age and obesity duration. Older adults and those who have carried significant excess weight for many years tend to have higher baseline rates of gallbladder disease.

Low-fat diet patterns. The gallbladder contracts most vigorously in response to dietary fat. Diets very low in fat reduce gallbladder stimulation, which can allow bile to stagnate. This is worth discussing with your provider if you are following an extremely low-fat eating pattern.

---

Symptoms That Need Prompt Attention

Many gallstones cause no symptoms and are discovered incidentally on imaging. When symptoms do occur, they can range from mild to severe. Knowing what to watch for is important.

Biliary colic is the classic presentation: intermittent, cramping pain in the right upper abdomen or epigastric area, often occurring one to two hours after a fatty meal. The pain can radiate to the right shoulder or back. Episodes typically last thirty minutes to a few hours and then resolve. While uncomfortable, this pattern is not a medical emergency, though it does warrant evaluation.

Acute cholecystitis - inflammation of the gallbladder, usually from a stone blocking the bile duct - presents as persistent right upper quadrant pain (lasting more than six hours), fever, nausea, and vomiting. This requires urgent medical attention.

Cholangitis and biliary obstruction - if a stone passes into the common bile duct, it can cause obstruction and infection. Symptoms include jaundice (yellowing of the skin or eyes), dark urine, fever, and severe pain. This is a medical emergency.

If you experience persistent abdominal pain, fever with abdominal symptoms, or yellowing of the skin or eyes, contact your healthcare provider immediately or go to the emergency room.

---

What Your Provider Can Do

If you develop gallbladder symptoms while on tirzepatide, your provider has several options.

Imaging evaluation. An abdominal ultrasound is the standard first step and can identify most gallstones and signs of gallbladder inflammation. It is non-invasive and widely available.

Continuing vs. pausing medication. The decision about whether to continue tirzepatide depends on symptom severity, the nature of the gallbladder finding, and your overall treatment goals. Asymptomatic gallstones discovered incidentally may not require stopping treatment. Active cholecystitis typically does.

Ursodeoxycholic acid. Some providers use this bile acid supplement preventively in patients at high risk for gallstones during rapid weight loss, though evidence for this approach specifically during GLP-1 therapy is still accumulating.

Surgical consultation. Symptomatic gallstones that do not resolve typically require cholecystectomy (surgical removal of the gallbladder), which can usually be performed laparoscopically with a short recovery.

Do not stop tirzepatide without discussing it with your provider first, even if you experience abdominal discomfort. Mild nausea and general GI symptoms are common on GLP-1 medications and do not require stopping treatment.

---

---

Practical Steps to Reduce Risk

While no intervention eliminates gallstone risk during weight loss, a few evidence-informed practices may help.

Lose weight at a steady pace. Faster is not always safer. Very rapid weight loss (more than 1.5 to 2 lbs per week on average) increases biliary cholesterol saturation more sharply. Following your prescribed dosing schedule rather than escalating faster than indicated helps keep weight loss at a pace the body can manage.

Include healthy fats in your diet. Fats stimulate gallbladder contraction, which clears bile regularly and reduces the opportunity for crystallization. Going extremely low-fat may sound appealing for weight loss, but it reduces the regular gallbladder emptying that helps prevent stone formation. Olive oil, avocado, nuts, and fatty fish provide dietary fat in a heart-healthy pattern.

Stay hydrated. Adequate fluid intake supports bile dilution and normal gallbladder function.

Report new symptoms early. Early evaluation of intermittent right upper quadrant discomfort often catches gallstone disease before it becomes a more complicated acute problem.

---

The Bottom Line

Gallbladder side effects are a real and recognized risk with tirzepatide, as they are across the GLP-1 receptor agonist class. The mechanism involves a combination of rapid weight loss effects on bile composition and GLP-1-mediated changes in gallbladder motility. Clinical trial data from SURMOUNT-1 and SURMOUNT-2 confirm that gallbladder events occur and are included in the safety monitoring for these medications.

At the same time, available comparative data suggest tirzepatide may carry a different, possibly lower, gallbladder risk profile than semaglutide - though this finding is preliminary and the research is ongoing. The absolute risk for any individual patient remains relatively low, and most people who develop gallstones on tirzepatide do not progress to acute complications.

Being informed about the risk, knowing the symptoms to watch for, and maintaining regular contact with your prescribing provider are the most important steps you can take. If you have a personal history of gallstones or other known risk factors, discuss them with your provider before starting tirzepatide so you can be monitored appropriately.

---

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. *N Engl J Med.* 2022;387(3):205-216. PMID: 35658024.
2. U.S. Food and Drug Administration. Prescribing Information: Mounjaro (tirzepatide) injection. Eli Lilly and Company. Updated 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215866s007lbl.pdf
3. Albadawy R, Tahir A, Aborayah H, et al. The effects of GLP-1 receptor agonists on the hepatic and biliary system: a systematic review and meta-analysis. *Ann Saudi Med.* 2025;45(2):78-92.

> Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication. > > Compounding Disclaimer: Compounded tirzepatide is not an FDA-approved medication. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded tirzepatide is not the same as, equivalent to, or interchangeable with FDA-approved tirzepatide products (Mounjaro or Zepbound). > > Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed. > > Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC (DBA Prescriva) is a management services organization and does not practice medicine or make clinical decisions. > > Brand Disclaimer: Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Prescriva is not affiliated with, endorsed by, or sponsored by these companies.